Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
editas medicine
5
×
life sciences
national blog main
biotech
crispr
national top stories
boston
crispr-cas9
gene editing
san francisco blog main
san francisco top stories
broad institute
cancer
crispr therapeutics
david liu
intellia therapeutics
katrine bosley
national
new york blog main
advaxis
agios therapeutics
aimmune therapeutics
alder biopharmaceuticals
alexander hardy
allergan
andrew oxtoby
babies
base editing
beam therapeutics
biotech week boston
boulder/denver blog main
boulder/denver top stories
branden moriarty
breakup
bridge bio pharma
bristol-myers squibb
bwb
cas13
What
medicine
5
×
crispr
cas
editas
editing
gene
ceo
katrine
allergan
beam
benefiting
big
bio
blessing
bosley
bosley's
bosley’s
boston
bridge
bucks
cancer
cells
check
clinical
coming
crime
cusp
defect
depart
departure
diagnostics
drive
edited
editor
exit
experimental
fears
flag
founders
genetic
Language
Current search:
medicine
×
" editas medicine "
×
@xconomy.com
5 years ago
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
6 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M